Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189443 | 0.95 | POLB (0.41) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL12118580 | 0.88 | NPSR1 (0.50) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL617921 | 0.87 | HDAC3 (0.41) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL10240339 | 0.87 | HDAC3 (0.44) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL617922 | 0.87 | HDAC3 (0.41) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL617828 | 0.86 | RXFP1 (0.40) | POLBRXFP1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL616107 | 0.86 | HDAC3 (0.43) | POLBRXFP1NPSR1LMNAMEN1 | |
| SCHEMBL4700326 | 0.86 | HTT (0.50) | POLBRXFP1NPSR1MEN1KMT2A | |
| SCHEMBL616752 | 0.85 | EGFR (0.43) | POLBNPSR1MEN1KMT2AHDAC3 | |
| SCHEMBL3303324 | 0.85 | MEN1 (0.41) | POLBRXFP1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | POLB 223/4885RXFP1 847/4885NPSR1 1837/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | POLB 223/4885RXFP1 847/4885NPSR1 1837/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | POLB 223/4885RXFP1 847/4885NPSR1 1837/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | POLB 223/4885RXFP1 847/4885NPSR1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.